COSMO Pharmaceuticals N.V. Logo

COSMO Pharmaceuticals N.V.

Specialty pharma for gastroenterology/dermatology, offering colon treatments & manufacturing services.

COPN | SW

Overview

Corporate Details

ISIN(s):
NL0011832936
LEI:
724500OX0EBQRYTVV639
Country:
Netherlands
Address:
Sir Rogerson's Quay Riverside II, Dublin 2 Dublin
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

COSMO Pharmaceuticals N.V. is a specialty pharmaceutical company focused on developing and commercializing products for gastroenterology, dermatology, and healthtech. The company's therapeutic focus is on the oral and endoscopic treatment of colon diseases, including bowel diseases and colorectal cancer prevention, utilizing its proprietary MMX® technology. In addition to its own pipeline, Cosmo provides manufacturing services to other pharmaceutical companies. These services cover the production of solid, semi-solid, and liquid oral medicines and include process assessment, technology transfer, stability testing, market release, and regulatory documentation support.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-21 02:00
Regulatory News Service
Cosmo Pharmaceuticals receives regulatory approval by the European Commission f…
English 6.1 KB
2025-10-21 02:00
Regulatory News Service
Cosmo Pharmaceuticals erhält nach positiver Stellungnahme des CHMP die behördli…
German 7.2 KB
2025-10-07 02:00
Regulatory News Service
Cosmo Pharmaceuticals announces regulatory approval of Winlevi® in South Korea
English 5.2 KB
2025-10-07 02:00
Regulatory News Service
Cosmo Pharmaceuticals gibt die behördliche Zulassung von Winlevi® in Südkorea b…
German 6.2 KB
2025-08-27 02:00
Regulatory News Service
Cosmo Receives Positive CHMP Opinion for Winlevi® for Treatment of Acne in Adul…
English 7.4 KB
2025-08-27 02:00
Regulatory News Service
Cosmo erhält positive CHMP-Stellungnahme für Winlevi® zur Behandlung von Akne b…
German 8.8 KB
2025-08-08 02:00
Regulatory News Service
Cosmo and Takeda Renew Strategic Manufacturing Agreement for Global Supply of O…
English 4.7 KB
2025-08-08 02:00
M&A Activity
Cosmo und Takeda verlängern ihre strategische Produktionsvereinbarung für die w…
German 5.0 KB
2025-08-06 02:00
Business and Financial Review
Cosmo Pharmaceuticals Confirms No Exposure to Proposed U.S. Tariffs and Reaffir…
English 3.3 KB
2025-08-06 02:00
Earnings Release
Cosmo Pharmaceuticals bestätigt, dass keine Auswirkungen durch geplante US-Zöll…
German 4.0 KB
2025-07-23 02:00
Earnings Release
Cosmo Delivers Strong Performance in H1 2025, Raises Full-Year EBITDA Guidance …
English 22.3 KB
2025-07-23 02:00
Earnings Release
Cosmo liefert starke Ergebnisse im ersten Halbjahr 2025, erhöht EBITDA-Guidance…
German 24.4 KB
2025-07-17 02:00
Regulatory News Service
Cosmo announces launch of Winlevi® for Treatment of Acne in Singapore and Malay…
English 9.5 KB
2025-07-17 02:00
Regulatory News Service
Cosmo: Markteinführung von Winlevi® zur Behandlung von Akne in Singapur und Mal…
German 10.7 KB
2025-07-16 02:00
Environmental & Social Information
Cosmo Accelerates Global ESG Leadership with Major Ratings Upgrades, UN Compact…
English 6.4 KB

Automate Your Workflow. Get a real-time feed of all COSMO Pharmaceuticals N.V. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for COSMO Pharmaceuticals N.V.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for COSMO Pharmaceuticals N.V. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
MEDICOX Co., Ltd. Logo
Developing new drugs and building a distribution platform for healthcare solutions.
South Korea 054180
Medigene AG Logo
Clinical-stage immuno-oncology firm developing TCR-engineered T cell therapies for solid tumors.
Germany MDG1
MedinCell S.A. Logo
Develops long-acting injectable therapies using proprietary technology to impact global health.
France MEDCL
A CDMO for cell therapy and regenerative medicine development & manufacturing.
Japan 2370
Medios AG Logo
Compounding patient-specific therapies and supplying specialty pharma for complex conditions.
Germany ILM1
Develops cord blood stem cell therapies for osteoarthritis & infant lung disease, plus banking.
South Korea 078160
Medizen Humancare Inc Co., Ltd Logo
Offers DTC genetic testing and genomic analysis for personalized disease risk prediction.
South Korea 236340
Medy-Tox Inc. Logo
Develops and markets botulinum toxins and dermal fillers for global aesthetic & therapeutic use.
South Korea 086900
Meito  Sangyo  Co., Ltd. Logo
Produces food products and specialty chemicals for industrial and pharmaceutical applications.
Japan 2207
Merck KGaA Logo
A science & tech firm in healthcare, life science, and electronics, advancing human progress.
United States of America 6MK

Talk to a Data Expert

Have a question? We'll get back to you promptly.